Allergan's (AGN) Tobira (TBRA) Deal Highlights Intercept (ICPT) and NASH Opportunity - Baird

September 20, 2016 10:27 AM EDT Send to a Friend
Baird analyst Brian Skorney reiterated his Outperform rating and $332 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after Allergan announced ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login